Product
Oxervate
Aliases
Cenegermin
Name
OXERVATE
INN Name
cenegermin-bkbj
FDA Approved
Yes
2 clinical trials
1 organization
2 indications
1 document
Indication
Dry Eye SyndromeIndication
Dry EyeClinical trial
A 4-week,Phase III, Multicenter, Double-masked, Vehicle-controlled Clinical Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) 20 mcg/mL Ophthalmic Solution Versus Vehicle, in Patients With Severe Sjogren's Dry Eye Disease Under Treatment With Cyclosporine A (PROTEGO-2 Study).Status: Completed, Estimated PCD: 2023-03-02
Clinical trial
A 4-week, Phase III, Multicenter, Double-masked, Vehicle-controlled Clinical Study to Evaluate Safety and Efficacy of Oxervate® (Cenegermin) 20 mcg/mL Ophthalmic Solution Versus Vehicle, in Patients With Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)Status: Active (not recruiting), Estimated PCD: 2023-02-03
Document
DailyMed Label: OXERVATEOrganization
Dompé farmaceutici S.p.A.